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  Candidate antibacterials are usually identiﬁ  ed on the basis of their   in vitro   activity. However, 
the apparent inhibitory activity of new leads can be misleading because most culture media 
do not reproduce an environment relevant to infection   in vivo  . In this study, while screening 
for novel anti-tuberculars, we uncovered how carbon metabolism can affect antimicrobial 
activity. Novel pyrimidine  –  imidazoles (PIs) were identiﬁ  ed in a whole-cell screen against 
  Mycobacterium tuberculosis  . Lead optimization generated   in vitro   potent derivatives with 
desirable pharmacokinetic properties, yet without   in vivo   efﬁ  cacy. Mechanism of action studies 
linked the PI activity to glycerol metabolism, which is not relevant for   M. tuberculosis   during 
infection. PIs induced self-poisoning of  M. tuberculosis  by promoting the accumulation of glycerol 
phosphate and rapid ATP depletion. This study underlines the importance of understanding 
central bacterial metabolism   in vivo   and of developing predictive   in vitro   culture conditions as a 
prerequisite for the rational discovery of new antibiotics.                
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 T
he fi  eld of anti-tuberculosis drug discovery culminated in 
the 1960s with the incorporation of rifampicin and pyrazi-
namide in the tuberculosis drug regimen. Th  e use of these 
two antimicrobials, in combination with isoniazid, ethambutol 
and  /  or streptomycin, represents a landmark in the treatment of 
human tuberculosis and resulted in the implementation of short-
course chemotherapy (SCC), reducing the time of treatment from 
18 to 6 months  1 – 3  . Short-course chemotherapy contributed towards 
controlling tuberculosis burden for the next 20 years. Nevertheless, 
tuberculosis cases started to rise again in the 1990s under the pres-
sure of the HIV pandemic and the emergence of multidrug-resistant 
(MDR) and extremely drug-resistant (XDR) tuberculosis strains. 
MDR strains are resistant to at least isoniazid (INH) and rifampicin 
(RIF), whereas XDR strains are MDR isolates that are addition-
ally resistant to fl  uoroquinolones and to one of the three injectable 
drugs capreomycin, amikacin and kanamycin. Th   e emergence and 
dissemination of MDR and XDR isolates, estimated to account for 
more than 400,000 new cases per year, impart new challenges in 
tuberculosis control  4  . Indeed, current treatment of drug-resistant 
tuberculosis requires 18  –  36 months and is associated with an unac-
ceptable rate of treatment failure and relapse. Consequently, devel-
oping new compounds active against MDR and XDR tuberculosis 
constitutes a main objective in anti-tuberculosis drug discovery. In 
addition, new antimycobacterial agents should ideally contribute to 
shorten tuberculosis treatment to 2 months or less  5,6  . Few promis-
ing drug candidates fulfi  lling these criteria have been discovered in 
recent years  7 – 9  . Of particular interest is TMC207, which has been 
shown to be highly active in proof-of-concept trials, and shows the 
potential to shorten the duration of therapy  10  . Nonetheless, given 
the number of tuberculosis cases and the rate of emergence of drug 
resistance, more compounds are clearly needed to combat and have 
a signifi  cant impact on the control and spread of tuberculosis. 
  Target- and cell-based screens are the two main approaches 
used to identify new antibacterials. With the recent development of 
miniaturized high-throughput screening technologies and meth-
ods such as fragment-based screening  11 , target-based screens seem 
very attractive as they allow for the rational discovery and optimi-
zation of new antibacterial leads. However, these approaches have 
failed to meet expectations and have proved to be unsuccessful 
in the identifi  cation of novel antimicrobials in general  12 .  Reasons 
for this lack of success are not entirely clear but may be partially 
attributed to the lack of a validated target, and the diffi   culty in 
predicting the biological eff  ect on target inhibition on the whole 
bacterium  13  . In contrast, all existing antibacterials on the market 
and  /  or in clinical development have been identifi  ed through cell-
based screening methods. Th   e major advantage of cellular screens 
lies in the possibility of identifying compounds with a complex 
and pleiotropic mode of action resulting in cellular death  13,14 .  Such 
a category of compounds cannot be rationally obtained from a 
classical target-based screen. 
  A common issue inherent to target- and cell-based assays is the 
limited predictive value of the  in vitro  culture conditions used to test 
novel compounds. Th   is limitation is not restricted to tuberculosis 
drug development, as recently illustrated while validating the type II 
fatty acid synthesis (FASII) pathway as a drug target against Gram-
positive bacteria  15 .  Th   e FASII pathway was proposed to be an attrac-
tive target based on genetic essentiality  in vitro  and on the discovery 
of promising lead candidates  16 – 18  . However, Gram-positive bacteria 
were shown to acquire complex host-derived lipids   in vivo ,  bypass-
ing the essentiality of the FASII system described   in vitro  15 ,  thereby 
rendering the FASII pathway futile as a drug target. Th  is  observa-
tion highlights the need to develop predictive  in vitro   culture condi-
tions for screening and testing new antibiotics. 
  Most culture media currently used for anti-tubercular compound 
testing were all developed empirically several decades ago for optimal 
propagation of the bacilli  in vitro  19 – 22 . Th   ese media were not optimized 
for drug screening, nor were they meant to reproduce the environ-
mental conditions encountered in the infected host. Th   is study under-
lines the largely overlooked yet crucial importance of culture condi-
tions and its impact on the disconnect between   in vitro   potency and 
  in vivo   effi   cacy in antibacterial drug discovery. Here, a new class of 
compounds active against   Mycobacterium tuberculosis   was  identifi  ed 
through a whole-cell screen. Despite excellent   in vitro   activity  and 
desirable pharmacological properties, the optimized compounds were 
found to be inactive in a tuberculosis mouse model. Th  e  disconnect 
between   in vitro   activity and   in vivo   effi   cacy was explained by a major 
diff  erence in carbon metabolism between bacteria replicating in stand-
ard tuberculosis broth medium as compared with infected lungs.   
 Results  
  Identifi  cation of a new class of anti-tubercular compounds   .     A  
cellular screen was developed to identify mycobacterial growth 
inhibitors. Th   e screen was carried out against   M. bovis   BCG using 
intracellular ATP content as a surrogate marker of bacillary growth. 
Compound hits with confi  rmed activity against  M. tuberculosis  were 
chemically clustered to identify any emerging structure  –  activity 
relationship. Our attention was drawn to a cluster of pyrimidine  –
  imidazole (PI) compounds comprising fi  ve compounds with an 
MIC  50   ranging  from  0.11  to      >    20    μ M  ( Supplementary  Table  S1 ).  Th  e 
compounds were bactericidal and the cytotoxic profi  le was within 
an acceptable range (  Supplementary Table S1  ). Th  erefore, a lead 
optimization programme was initiated with the goal of achieving 
desirable   in vivo   PK properties while retaining the potent anti-
tubercular  activity.   
  Optimized PI compounds are not effi   cacious   in vivo     .    A  total  of 
324 derivatives were synthesized. Compounds   1 ,   2   and   3   ( Table  1 ) 
were selected for effi   cacy testing in the mouse model.   In vivo   PK 
studies in the mouse revealed oral bioavailability ranging between 
50 and 100  %   (  Table 2  ). Following a dose of 25      mg      kg      −     1 ,  lung  lev-
els were above the minimum inhibitory concentration (MIC) for 
30  –  100  %   of the dosing interval (  Table 2  ). Additional PK studies at 
100   mg   kg     −     1   showed that exposure of   3   was proportional to dose, 
providing plasma and lung levels were above the MIC for the entire 
dosing interval (  Table 2  ). Pharmacokinetic  /  pharmacodynamic 
(PK  /  PD) indices corrected for protein binding were favourable, 
with   3   at  100   mg   kg     −     1   showing PK  /  PD indices similar to those of 
  Table  1       |     Structure  and  biological  activity  of  the  PI  compounds .
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     Abbreviations:  CC 50  , cytotoxic concentration 50  %  ; MIC  50  , minimum inhibitory concentration 
50 % ;  ND,  not  determined.   
     The  MIC 50   was determined against   M. tuberculosis   H37Rv. Cytotoxicity (CC  50  ) was determined 
in two cell lines, BHK21 and HepG2. Assays were carried out at least two times in triplicates.     ARTICLE   
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isoniazid ( Table 2 ). However, when tested in the tuberculosis mouse 
model at 25 and 100     mg     kg      −     1  , all three compounds were found to be 
ineff  ective in reducing lung bacterial loads, despite 28-day courses 
of daily dosing (  Fig. 1  ; data not shown). 
 Th  ese results underline how anti-tubercular compounds with 
good   in vitro   activity and good PK  /  PD properties can still be with-
out   in vivo   activity.   
  PI compounds are inactive in the absence of glycerol   .    I n  a n  a t t e m p t  
to understand the disconnect between   in vitro   activity and   in vivo  
effi   cacy of the PI compounds,   M. tuberculosis   spontaneous mutants 
resistant to   2   were isolated. Th   e clones obtained were highly resist-
ant to the PI compounds with MIC  50   values  greater  than  20    μ M.  In 
addition, the spontaneous mutants resistant to  2  were cross-resistant 
to  1  and  3 , with MIC  50  greater than 20    μ M. Full-genome sequencing 
of four independently isolated resistant mutants revealed a single 
polymorphism in   glpk  , which encodes for glycerol kinase (GlpK, 
Rv3696c), the fi  rst committing enzyme for glycerol metabolism in 
most bacteria. One of the four clones showed a single-nucleotide 
polymorphism at codon 187 (  187 GGG    >     187 G T G),  whereas  the  other 
three clones harboured a frameshift   mutation due to the inser-
tion of a guanine in codon 191 (  191 GGT    >     191 GG G T).  Mutation 
  191 GGT    >     191 GG G T  was  identifi  ed by sequencing in fi  ve additional 
spontaneous-resistant mutants. Interestingly, the same frameshift   
mutation is naturally found in some   M. bovis   strains, a species una-
ble to metabolize glycerol  23 .   M. bovis   BCG, the mycobacterial spe-
cies used for the whole-cell screen, can metabolize glycerol and has 
no frameshift   mutation in   glpK  23  . Consistently, none of the spon-
taneous-resistant mutants was able to multiply in the presence of 
glycerol as the sole carbon source (  Fig. 2a,b  ). 
  To unambiguously link the activity of the PI compounds to the 
ability to metabolize glycerol, we constructed an   M. tuberculosis  
knockout strain defi  cient for the expression of GlpK (MTB  Δ  glpK ). 
Th  e MTB  Δ  glpK   mutant strain was found resistant to the PI 
  compounds, whereas sensitivity was restored on re-introduction of 
a wild-type copy of   glpK   in the KO strain (  Fig. 2c  –  e  ). Th  ese  results 
showed that glycerol dissimilation is required for the anti-tubercular 
activity of the PI compounds. Glycerol has long been known to 
be the preferred source of energy and carbon for   M. tuberculosis  
under   in vitro   conditions 19 – 21,24,25  . As such, glycerol is present in 
most standard   M. tuberculosis   growth media  19,21,26  , including the 
culture medium used here to identify the PI compounds  26 ;  a  bias 
towards glycerol-dependent killing mechanisms may thus have 
resulted in the selection of the PI compounds. Th  is hypothesis 
was supported by the observation that PI compounds were inac-
tive against   M. tuberculosis   in the absence of glycerol in the culture 
medium, whereas the inhibitory eff  ects of reference compounds 
such as   isoniazid, streptomycin and moxifl  oxacin were comparable 
(  Fig. 2f  ). Similar results were obtained when using newly isolated 
clinical isolates of   M. tuberculosis   (  Supplementary Table S2  ), ruling 
out the possibility that the glycerol-dependent killing mechanisms 
of the PI compounds are restricted to the laboratory strain H37Rv, 
which has been propagated   in vitro   on glycerol-containing medium 
for about 100 years  27 . Finally, the absence of growth inhibitory activ-
ity of PI compounds   in vivo   suggests that glycerol is not a carbon 
source either readily available or primarily used by   M. tuberculosis  
in mouse lungs. Accordingly, the MTB   Δ  glpK   mutant strain colo-
nized mouse lungs as eff  ectively as its parental counterpart (  Fig. 3  ), 
     Table  2       |     PK / PD  parameters  of  1 – 3. 
       1     2     3     3     INH     EMB  
    Parameter (units)                    
   Dose  (mg   kg     −     1 )    25     25     25     100     25     100  
    C  max   ( μ g   ml     −     1 )   4.0   3.8   3.0   8.9   28   2.5 
    T  max   (h)   1.0   0.5   0.5   0.5   0.25   0.5 
   AUC  ( μ g *    h   ml     −     1 )   23.4   10.6   12.4   59.3   52   8 
   Lung  AUC  ( μ g  *   h   g     −     1 )   10.2   10.7   17.5   ND   ND   145 
    T  1 / 2   (h)   2.5   2.2   2.3   3.0   1.7   1.8 
   F  ( % )   100   100   50     50         
   AUC / MIC   71.4   44.4   758.2   3630.6   1305   13 
   T    >    MIC  ( % )   42   38   73   100   68   17 
    f AUC / MIC   8.6   17.8   113.7   544.6   757   10 
    f T    >    MIC  ( % )   10   26   47   82   62   15 
   Lung  AUC / MIC   31.2   44.8   1070.6   4654.8   *      ND   247 
   Lung  T    >    MIC   32   54   100   100   ND   ND 
          Abbreviations: AUC, area under the curve extrapolated to     ; AUC  /  MIC, ratio between plasma exposure and minimum inhibitory concentration (MIC);   C  max  , maximum concentration of drug in plasma; 
  f  , free fraction (indicates PK  /  PD parameters corrected for plasma protein binding); F, oral bioavailability; ND, not determined;   T  max  , time to maximum concentration of drug in plasma;   T  1 / 2 ,  half-life; 
T       >       MIC, percentage of the dosing interval during which plasma levels exceed the MIC.     
          Pharmacokinetic parameters were determined in the mouse model after a single oral dose of 25     mg     kg      −     1   for    1   and   2  , and single oral doses of 25 and 100     mg     kg      −     1   for    3   to establish dose proportionality. 
PK  /  PD indices of two standard anti-TB agents at efﬁ  cacious doses, isoniazid 25     mg     kg      −     1   (INH) and ethambutol 100     mg     kg      −     1   (EMB), are provided for the sake of comparison.     
    *         Extrapolated assuming lung exposure proportional to dose since plasma PK is linear.     
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   Figure  1     |           In vivo   activity of compound   3   in the mouse model.  Balb / C  mice 
were infected intranasally with  ~ 10 3    M. tuberculosi  s H37Rv. Drug treatment 
was initiated 1 week after infection and was administered orally for 28 
days  daily  at  25   mg   kg     −     1   (red  circles)  and  100   mg   kg     −     1   (blue diamonds). 
Bacterial loads were determined after 14 and 28 days of drug treatment and 
compared with the control group (HP  β  CD formulation alone, black squares). 
Isoniazid (green triangles, 25     mg     kg      −     1  ) was used as a positive control.   ARTICLE
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showing that   M. tuberculosis   glycerol dissimilation is dispensable in 
the mouse model of tuberculosis.     
  Accumulation of glycerol phosphate in PI-treated mycobacteria   .  
  Th  e PI compounds are only active in the presence of glycerol, 
suggesting that they might exert their inhibitory eff  ect  by 
dysregulating the glycerol dissimilation pathway. Glycerol phos-
phate and dihydroxyacetone phosphate (DHAP) are the fi  rst two 
specifi  c metabolites of the glycerol dissimilation pathway (  Fig. 5  ). 
As the accumulation of sugar phosphates is known to be highly 
toxic for most bacteria  28 – 31  , the toxicity of both metabolites was 
tested against   M. tuberculosis  . Glycerol phosphate and DHAP were 
added exo  genously to   M. tuberculosis   cultures and the eff  ect on 
growth was determined. Results showed that glycerol phosphate 
and DHAP were toxic for   M. tuberculosis  , showing an MIC  50   value 
of 12.5 and 1.2     mM respectively (  Fig. 4a  ). Th   e low potency might 
be because of a limited uptake of phosphorylated metabolites 
inside   M. tuberculosis  . Similarly, aldehyde methylglyoxal, a spontane-
ous glycolytic by-product that accumulates when the pool of sugar 
phosphate increases  32 – 34   (  Fig. 5  ), was also shown to be toxic, with 
an MIC  50   value of 0.4     mM (  Fig. 4a  ). We then tested whether the PI 
compounds induced the intracellular accumulation of these toxic 
metabolites. Th  e  eff  ect of 1 on the mycobacterial metabolome was 
studied by liquid chromatography  /  mass-spectrometry (LC  /  MS) 
24   h  aft  er treatment. An early time point was chosen to discrimi-
nate specifi  c changes induced by the compounds rather than by a 
general stress response associated with growth arrest and  /  or 
cell death. A signifi  cant accumulation of glycerol phosphate was 
observed specifi  cally in cells treated with   1   and   2   (  Fig. 4b  ). No 
changes in the levels of DHAP, or of the downstream glycolytic 
metabolites glyceraldehyde phosphate and pyruvate, were detected 
( Fig.  4c ).  Th  ese data suggested that the accumulation of glycerol 
phosphate might be one of the toxic consequences induced by the 
PI compounds in the presence of glycerol in the broth medium and 
of a functional glycerol   dissimilation pathway. A second feature of 
PI compounds was the promotion of a very rapid ATP depletion in 
  M. tuberculosis  , which was not observed with the reference com-
pounds streptomycin and moxifl  oxacin (  Fig. 4d  ). We showed that 
the ATP pool was depleted by >75  %   in cells treated with   1   and   2   in 
the presence of glycerol as early as 24     h aft  er treatment (  Fig. 4d  ). 
Taken together, these results suggest that high intracellular levels 
of glycerol phosphate combined with rapid depletion of the intra-
cellular ATP pool are specifi  cally associated with the anti-tubercular 
activity of the PI compounds. 
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  Figure  3     |          Glycerol  metabolism  is  not  required  for  the  virulence  of 
  M. tuberculosis in vivo  . Balb  /  C mice were infected intranasally with   ~  10  3  
bacilli of the parental H37Rv (black circles) or of the   Δ  glpK   (red squares) 
  M. tuberculosis   strains. The bacterial burden was followed in the lungs by 
CFU enumeration. Four mice per time point of each group were used and 
the standard deviations are shown.   
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    Figure  2     |          Glycerol  dissimilation  is  required  for  the  anti-tubercular 
activity of the PI compounds.   M. tuberculosis   H37Rv (red squares) and 
spontaneous mutants resistant to   2   (clones 1  –  9, other symbols) were 
incubated in a medium containing a complex mixture of carbon sources 
(7H9 medium,   a  ), or in a medium containing glycerol as the sole carbon 
source (Sauton medium,   b  ). Growth was monitored by following the OD  600  
over time. The MIC  50   of   1   (red circles) and   2   (blue squares) was tested 
against the parental H37Rv strain (  c ,   f  ), H37Rv   Δ  glpK   strain (  d  ) and H37Rv 
  Δ  glpK   pMV306- glpK   ( e  ) in the presence (  c  –  e  ) or absence (  f  ) of glycerol. 
Streptomycin (black triangles) was used as a reference compound.   
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       Figure  4     |          Accumulation  of  glycerol  phosphate  and  rapid  ATP  depletion 
in PI-treated   M.  tuberculosis. (  a )  MIC 50   values of glycerol phosphate 
(black squares), DHAP (blue triangles) and methylglyoxal (red diamonds) 
were determined for   M. tuberculosis   H37Rv.   M. tuberculosis   H37Rv was 
exposed to   1   and   2   in the presence of glycerol for 24     h. The relative 
abundances of glycerol phosphate (  b  ) and of pyruvate (  c  ) are shown. 
  M. tuberculosis   H37Rv was exposed to   1   and   2   in the presence of glycerol 
for 24     h. The intracellular ATP level was quantiﬁ  ed (  d  ). Streptomycin and 
moxiﬂ  oxacin were used as reference compounds.   ARTICLE   
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 Th  e eff  ects triggered by the PI compounds, that is, accumula-
tion of glycerol phosphate combined with rapid ATP depletion, 
reproduce almost entirely the phenotypes described for an 
  Escherichia coli   glycerol phosphate dehydrogenase knockout 
mutant  35  , suggesting that glycerol phosphate dehydrogenase may 
be the primary target of the PIs. However, we developed an enzy-
matic assay from   M. tuberculosis   cell-free extracts and showed that 
PI compounds do not directly inhibit   M. tuberculosis   glycerol  phos-
phate dehydro  genase activity (data not shown).     
  Putative glyoxylase rv0577 is a candidate target of PIs   .    To  iden-
tify the candidate targets of the PI compounds, an affi   nity chromato-
graphy approach was undertaken, whereby an active PI derivative 
(compound   4  ,   Fig. 1  ) covalently linked to sepharose beads was co-
incubated with mycobacterial cell lysate, in both the presence and 
the absence of unbound  4 . Bound proteins were separated in  parallel 
by SDS  –  polyacrylamide gel electrophoresis, trypsin-digested and 
identifi  ed by mass spectrometry. A quantitative comparison of these 
experiments identifi  ed four candidate proteins (Rv0577, Rv0911, 
Rv2298 and lldD2) predicted to be involved in the methyl  glyoxal 
detoxifi  cation pathway (  Fig. 5  ), the binding of which dramatically 
decreased in the presence of free   4 .  Specifi  cally, Rv0577, Rv2298 
and Rv0911 are homologues of known glyoxylases or aldo  /  keto 
  reductases, whereas lldD2 is annotated as a non-  respiratory   lactate 
dehydrogenase (cytochrome). Th   e most abundant of the four  proteins, 
Rv0577, was chosen for further investigation as a potential target of 
the PI compounds, and thus an   M. tuberculosis   strain overproducing 
Rv0577 (MTB pMV262-  rv0577  ) was constructed. Interestingly, 
MTB pMV262- rv0577  multiplied 25 %  faster than the parental strain 
on glycerol-containing medium. Th   is observation suggests that the 
product of   rv0577   might participate in the detoxifi  cation of glycerol 
metabolism by-products. It is important to note that MTB pMV262-
  rv0577   showed an increased resistance to   1   and   2   compared with the 
parental strain (  Table 3  ), strongly supporting the notion that Rv0577 
is one of the primary targets of the PI compounds.       
 Discussion 
  Historically, the discovery of new antibiotics has been   primarily 
 serendipitous. Although the value of this approach is unquestion able, 
little has been learned from the successes and failures   encountered 
in the processes. Current antibiotics are mainly derived from 
  natural sources and inhibit conserved   macromolecular machin-
eries such as DNA replication, protein or cell-wall   synthesis. Th  is 
narrow set of targets is truly and intrinsically essential for cell multi-
plication independent of the environment. With the explosion 
of drug resistance, there is a need to move from these historical 
targets to new and less conventional ones. However, the validation 
of new targets is more complex, as their essentiality might well be 
conditional and  /  or contextual. For instance, the metabolic target 
isocitrate lyase (ICL) of   M. tuberculosis   is strictly essential   in vivo , 
yet dispensable under classical   in vitro   culture  conditions 36,37 . 
  In this work, we report on the underappreciated importance 
of the culture medium composition, and in particular the nature 
of the carbon source, for anti-tuberculosis drug discovery. A new 
class of PI inhibitors was identifi  ed from a chemical genetic screen. 
Th  e PI compounds were potent in glycerol-containing medium 
  in vitro  , but without   in vivo   effi   cacy. Th   ese compounds were shown 
to be inactive against   M. tuberculosis   in the absence of glycerol or 
of a functional glycerol dissimilation pathway. Treatment with PI 
compounds resulted in the accumulation of glycerol phosphate 
coupled with rapid and sustained ATP depletion, thereby impairing 
  M. tuberculosis   growth and survival. Accumulation of sugar phos-
phate is known to be toxic for most prokaryotic and eukaryotic cells, 
but the basis of such toxicity is yet to be fully understood  28 – 31,35 .  In 
  E. coli  , unregulated glycerol metabolism triggers the spontaneous 
formation of toxic aldehyde methylglyoxal, the latter reacting with 
DNA and proteins, thus promoting the accumulation of advanced-
glycated end products and cell death  38  . Methylglyoxal is highly 
unstable and hence could not be detected in PI-treated mycobac-
teria. Nevertheless, affi   nity chromatography experiments identifi  ed 
four putative enzymes involved in methylglyoxal detoxifi  cation as a 
potential target for the PI compounds. Th   e most abundant protein 
identifi  ed by affi   nity chromatography was Rv0577. Strikingly, over-
production of this putative glyoxylase in   M. tuberculosis   resulted 
in a strong resistant phenotype to PI compounds, conceivably 
establishing a link between the antimycobacterial activity of the 
PI compounds and methylglyoxal detoxifi  cation in the bacterium. 
Th   e mechanism by which methylglyoxal is eliminated has not been 
studied in   M. tuberculosis  . Methylglyoxal is usually converted into 
pyruvate by lactate (  Fig. 5  ). Glutathione has a central role in meth-
ylglyoxal detoxifi  cation in enterobacteria and human cells, func-
tioning as a cofactor for most glyoxylases.   M. tuberculosis   does not 
produce glutathione and must therefore use an alternate cofactor 
that remains to be identifi  ed. Further validation is required to under-
stand the precise molecular mode of action of the PI compounds, 
and the link between the methylglyoxal detoxifi  cation pathway, the 
accumulation of toxic levels of glycerol phosphate and the depletion 
of the intracellular ATP pool. 
  Two additional potent compound series from the hit list were 
also found to be glycerol dependent, arguing for a bias in the screen-
ing process. Such bias may be explained by the design of the screen 
itself; mycobacteria were exposed to the compounds for only 48     h 
(two-generation times) and ATP was used as an indicator of cell 
biomass increase. Treatment with PI compounds triggered ATP 
Methylglyoxal
DHAP Glycerol Glycerol-P G3P
Intermediate
(lactoylglutathione)
Rv0577, Rv0911?
Rv0577, Rv0911?
MG reductase
Rv2298 ?
Lactaldehyde
Lactic acid
Pyruvate
Glo II
Glo I
lldD2
(lldD1)
Aldehyde
dehydrogenase
    Figure  5     |          Glycerol  metabolites  and  the  putative  methylglyoxal-
detoxiﬁ  cation pathway in  M. tuberculosis  . The generation of methylglyoxal 
from DHAP is usually spontaneous (dotted line). Glo I: glyoxylase I, 
Glo II: glyoxylase II, lldD: lactate dehydrogenase (cytochrome), G3P: 
glyceraldehyde-3-phosphate, DHAP: dihydroxyacetone phosphate.   
  Table  3       |     Overexpression  of  Rv0577  confers  resistance  to 
PI compounds in   M. tuberculosis . 
    
  MTB  H37Rv 
MIC  50   (  M)  
  MTB  pMV262- rv0577  
MIC  50   (  M)  
   1   0.35  ± 0.10   2.32 ± 0.40 
   2   0.34  ± 0.11   3.53 ± 1.13 
   Streptomycin   0.18 ± 0.02   0.12 ± 0.01 
   Isoniazid   0.42 ± 0.03   0.37 ± 0.05 
     Abbreviation:  MIC,  minimum  inhibitory  concentration.   
     The  MIC 50   of    1  ,   2  , streptomycin and isoniazid was tested against MTB H37Rv and MTB 
pMV262-  rv0577 .   ARTICLE
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depletion as early as 24      h aft  er incubation, a timeframe in which 
known antibiotics have no eff  ect, thus favouring the selection of 
those inhibitors the mode of action of which involves rapid ATP 
depletion. Such fast-acting properties are shared by compounds that 
target the glycerol dissimilation pathway, explaining the observed 
bias towards the selection of glycerol-dependent inhibitors. Several 
mechanisms might explain the rapid ATP depletion observed on 
treatment with PI compounds. Th  e  uncontrolled  phosphorylation 
of glycerol may function as an ATP sink, depleting the available 
ATP pool as described in   E. coli  35  . Alternatively, glycerol phosphate 
may lower ATP content through a direct inhibition of oxidative 
phosphorylation, as recently described for maltose phosphate in 
  M. tuberculosis  39 . 
  Complex host-derived lipids have been proposed to represent an 
essential source of carbon and energy for   M. tuberculosis in vivo ,  as 
evidenced by the attenuated phenotype of an   M. tuberculosis   strain 
defi  cient for ICL activity  19,21,25,36,37  . However,   M. tuberculosis   ICL  is 
an enzyme with dual functions involved in two distinct pathways  40 , 
and the glyoxylate shunt is required for growth not only on lipids 
but also on branched-chain amino acids, alcohol and sterols. It 
thus remains to be determined which carbon source(s) are used by 
  M. tuberculosis   in host tissues. 
  Finally, it is important to note that the results of studies on the 
mechanism of action of the PIs reported here have implications for 
how we approach antibacterial drug discovery. Th  e  current  concept 
is to inhibit an essential bacterial function, assuming that this would 
result in growth inhibition and death of the bacterium. However, 
the PIs show us a possible alternative approach, derailing meta-
bolic subsystems resulting in accumulation of toxic metabolites (for 
example, sugar phosphates) and the collapse of core homeostatic 
systems (for example, ATP level maintenance). Th  e conceptual 
similarities to other recent works showing how bactericidal antibi-
otics truly function are striking  13,14 .  Specifi  cally, bacterial cell death 
is caused not by simple target inhibition but by complex events 
that occur aft  er primary target modulation  13,14 .  Th  erefore,  targeting 
metabolic pathways known to generate toxic intermediates, such 
as the methylisocitrate cycle  41 – 43  , could represent an interesting 
approach to fi  nding new antibacterials. 
  In the light of the fi  ndings reported here, we believe that an in-
depth knowledge and understanding of central bacterial metabolism 
within host tissues is required for the rational discovery of new drugs 
eff  ective against   M. tuberculosis   and other pathogenic bacteria.     
 Methods  
  Strains and growth conditions   .       M. tuberculosis   H37Rv   (  ATCC  , cat. no. 27294) and 
derivative strains were maintained in Middlebrook 7H9 broth medium supplemented 
with 0.2  %   glycerol, 0.05  %   Tween 80 and 10  %   ADS supplement. Alternatively, 7H9 
medium without glycerol or Sauton medium  21   was used. Culture media were supple-
mented with hygromycin (50       μ g   ml     −     1  ) or kanamycin (20       μ g   ml     −     1 )  when  required.   
  High-throughput cell-based screen   .      M. bovis   BCG was cultured to an OD  600   of 
0.5  –  0.6 in complete 7H9 broth medium. In preparation for 1536-well dispensing, 
the culture was diluted to an OD  600   of 0.01 using complete 7H9 media. A volume 
of  4    μ  l of complete 7H9 media was dispensed into a white, solid bottom 1536-well 
plate using a custom   Bottle Valve   liquid dispenser (  GNF  ). A volume of 100     nl of 
test compound in DMSO (1     mM) was then transferred into each assay plates using 
a custom   1536 Pintool   (  GNF  ). Diluted culture (4       μ  l) was subsequently added to the 
assay plates using a Bottle Valve liquid dispenser (fi  nal OD  600   in  8    μ l  is  0.005).  Th  e 
plates were incubated at 37       °  C for 48     h. Growth was assessed by measuring ATP 
levels using the   BacTiter-Glo Microbial Cell Viability Assay   (  Promega  ). Lumines-
cence was measured using a ViewLux plate reader.     
  MIC  50   determination   .    MIC 50   were determined as previously described, with 
slight modifi  cations  44 .  Briefl  y, compounds dissolved in 90  %   DMSO were twofold 
serial-diluted in duplicates and spotted by   mosquito HTS   (  TTP LabTech  ) to 
384-well clear plates, resulting in 10 dilutions of each compound. A volume of 
50    μ  l of   M. tuberculosis   culture  (fi  nal OD  600   of 0.02) was added to each well, and 
the assay plates were incubated at 37       °  C for 5 days. OD  600   values were recorded 
using a SpectraMax M2 spectrophotometer, and MIC  50   curves were plotted using 
GraphPad Prism 5 soft  ware. Under the assay setting, MIC  50   values, which fall in the 
linear part of the inhibition curve, are more robust and reproducible than MIC  90 . 
Th   erefore, only MIC  50   values  are  reported.   
  Cytotoxicity   .    Cytotoxicity  was  tested  against  cell  lines   HepG2   ( ATCC ,  cat.  no. 
HB-8065) and   BHK21   (  ATCC  , cat. no. CCL-10) in 96-well microplates. Th  e  cells 
were seeded at a density of 10  5   cells per well, incubated at 37       °  C for 24     h and 
exposed to twofold serial-diluted compounds for 3 days. Cell viability was 
monitored using the   Cell Proliferation Kit II   (  Invitrogen  ).     
  Selection of spontaneous PI-resistant mutants   .      M. tuberculosis   H37Rv  was 
spread onto 7H11 plates containing 20       μ  M of the test compounds. Colonies were 
picked aft  er 3 weeks of incubation at 37       °  C and propagated into 7H9 medium. Th  e 
resistance phenotype to the PI compounds was confi  rmed by testing MIC  50   values 
against   1   and   2 .   
  Full-genome sequencing      .     Whole-genome fragment libraries were prepared us-
ing   Paired-End Sample Preparation Kit   (  Illumina  ). Briefl   y,  5    μ  g of each genomic 
DNA sample was fragmented using the nebulization technique for 10     min with 
compressed air of 32     p.s.i. Th   e ends were repaired with the addition of A base on 
the 3  ′   end and by ligation of paired-end adaptor oligo mix. Samples were then 
gel-purifi  ed and selected for 200     bp fragment size to be amplifi  ed by PCR, fol-
lowed by gel purifi  cation. DNA samples were hybridized onto the fl  owcell using a 
Paired-End Cluster Generation Kit v1, transferred to the Genome Analyzer Classic 
and 48 cycles of sequencing were performed using the 36 Cycle Sequencing Kit v2. 
Data Collection Sequence Control soft  ware version 2.3 was used on the Genome 
Analyzer I, and Pipeline version 0.3.0 was used for analysis. Th   e  resulting  7.8 – 9.6 
million reads were aligned to the   M. tuberculosis   H37Rv sequence using SOAP 
soft  ware. Nucleotide changes from the reference sequence were called in situations 
in which at least six separate reads called the alternate letter, and in which the sum 
of the Solexa quality scores for the alternate letter was fi  vefold greater than the sum 
of the Solexa quality score for the reference letter. Insertions and deletions were 
verifi  ed by assembling   de novo   contigs  with  Velvet.   
  Construction of the MTB    glpk   strain   .     Th  e    glpk   gene was knocked out by allelic 
exchange using plasmid pYUB854  45   as previously described  4 .  Th   e mutant strain 
MTB  Δ  glpk   was complemented with a wild-type copy of the   glpK   gene under the 
control of its own promoter and cloned into vector pMV306  46 .   
  Pharmacokinetic properties and oral bioavailability   .    CD-1  female  mice  were 
used for PK studies. Th   e compounds were formulated in 27  %   HP  β  CD, 6-N HCl, 
27  %   PBS and 27  %   citrate buff  er (pH 4). Th   e lung distribution properties of 
compounds were determined by LC  /  MS aft  er a single dose of 25 or 100     mg     kg      −     1  
of body weight.     
  Mouse efﬁ  cacy studies   .      In vivo   effi   cacy studies were determined aft  er intranasal 
infection of BALB  /  c mice with 10  3    M. tuberculosis   H37Rv. Treatment was initiated 
1 week aft  er infection. Compounds were administered daily by gavage for 
28 consecutive days. Bacterial loads were determined at 14 and 28 days aft  er the 
initiation of treatment. All procedures involving mice were reviewed and approved 
by the institutional animal care and use committee of the Novartis Institute for 
Tropical Diseases.     
  Metabolomics   .    For  metabolomic  profi  ling studies,   M. tuberculosis   was  culti-
vated on modifi  ed 7H10 agar plates. Bacteria were metabolically quenched by 
rapid transfer of bacteria-laden fi   lters  into  acetonitrile / methanol / H 2 O  (40:40:20), 
precooled to        −       40       °  C, and metabolites were extracted by mechanical lysis, followed 
by clarifi  cation and fi  ltration across a 0.22       μ m  fi  lter. Bacterial biomass of individual 
samples was determined by measuring the residual protein content. Metabolites 
were separated and analysed by dual-mode electrospray ionization time-of-fl  ight 
mass spectrometry using an   Agilent     Accurate Mass 6220 TOF  . Dynamic mass 
axis calibration was achieved by continuous infusion of a reference mass solution 
using an isocratic pump with a 100:1 splitter. Th  is  confi  guration achieved mass 
errors of approximately fi  ve parts per million, mass resolution ranging from 10,000 
to 25,000 (over   m  /   z   121 – 955   amu)  and  a  5  log 10   dynamic range. Detected ions 
were deemed metabolites on the basis of unique accurate mass-retention time 
(AMRT) identifi  ers for masses showing the expected distribution of accompanying 
isotopomers. Metabolite identities were established by querying against a pre-
populated AMRT library of metabolite standards and showing chromatographic 
co-elution of candidate metabolites with pure chemical standards spiked into 
representative biological samples.     
  Determination of intracellular ATP levels   .     Th   e intracellular ATP level was quan-
tifi  ed as previously described  47 .  Briefl   y,  25    μ l  of   M. tuberculosis   culture was mixed 
with an equal volume of freshly prepared BacTiter-Glo reagent in white 384 fl  at-
bottom plates and incubated in the dark for 5     min. Luminescence was measured 
using a   Tecan     Safi  re  2    plate  reader.   
  Protein pull-down experiments   .      M. bovis   BCG was grown to an OD  600   of 1 in 
7H9 medium. Cells were disrupted by bead-beating, and protein lysates were 
clarifi  ed by centrifugation.   4   was coupled to NHS-sepharose beads and incubated ARTICLE   
7
NATURE COMMUNICATIONS   |       DOI:   10.1038/ncomms1060 
NATURE COMMUNICATIONS   |   1:57   |     DOI:   10.1038/ncomms1060    |   www.nature.com/naturecommunications
© 2010 Macmillan Publishers Limited. All rights reserved.
with 5     mg of   M. bovis   BCG of protein lysate in the either presence (competition) 
or absence (control) of free   4 .  Aft  er three washing steps, bound proteins were 
separated in parallel by SDS  –  polyacrylamide gel electrophoresis, trypsin-digested 
and identifi  ed by LC  /  MS. Proteins that were identifi  ed with high confi  dence in 
repeat analyses of competition pull-downs but were absent or at greatly reduced 
levels as indicated by spectral counting in control pull-downs were reported as 
potential targets.     
  Overexpression of   Rv0577   in   M. tuberculosis     .      Rv0577   was  amplifi  ed by PCR 
and cloned into the multicopy expression vector pMV262 under the control of the 
mycobacterial hsp60 promoter  46 .                                       
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